Patent classifications
C07H15/00
Conformationally-preorganized, miniPEG-containing gamma-peptide nucleic acids
Described are -PNA monomers, methodology for synthesizing them, and methodology for synthesizing PNA oligomers that incorporate them.
Extracellular matrix sheet structures
A sheet structure formed from an extracellular matrix (ECM) composition that includes acellular ECM derived from small intestine submucosa (SIS) tissue, gentamicin and vancomycin. The sheet structure is configured to modulate inflammation of damaged biological tissue and induce cell and tissue proliferation, bioremodeling of the damaged biological tissue, and regeneration of new tissue and tissue structures with site-specific structural and functional properties, when the tissue structure is delivered to the damaged biological tissue.
Sulfated oligosaccharide derivatives
The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.
CALICHEAMICIN DERIVATIVES AND ANTIBODY DRUG CONJUGATES THEREOF
The present invention is directed to novel calicheamicin derivatives useful as payloads in antibody-drug-conjugates (ADC's), and to payload-linker compounds and ADC compounds comprising the same; to pharmaceutical compositions comprising the same and to methods for using the same to treat pathological conditions such as cancer.
Phosphoalkyl ribose polymers comprising biologically active compounds
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M, q, w and n are as defined herein. Methods associated with preparation and use of such compounds is also provided. ##STR00001##
Phosphoalkyl ribose polymers comprising biologically active compounds
Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, L, L.sup.1, L.sup.2, L.sup.3, L.sup.4, M, q, w and n are as defined herein. Methods associated with preparation and use of such compounds is also provided. ##STR00001##
Process for the preparation of high purity miglustat
A process for the preparation and isolation of crystalline miglustat without the use of a column chromatography or ion exchange purification. The crystalline miglustat has a high purity and a melting point of 128 C. and an endothermic peak is 133 C.
BETA-GLUCURONIDE-LINKER DRUG CONJUGATES
Ligand Drug conjugate compounds comprising a -glucuronide-based linker and methods of using such compounds are provided.
Tetracyclic anthraquinone derivatives
Disclosed are a compound represented by formula (I) and a pharmaceutically acceptable salt thereof, ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, W, n are defined as in the present application. Also disclosed is a method for treating cancer, comprising administering to a subject in need thereof a therapeutically effective amount of the compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The compound and a salt thereof according to the present application possess good anticancer and/or antitumor activity, and good water solubility and stability, as well as good tolerance in animal bodies. Also disclosed is a process for preparing a compound represented by formula (I) of the present application, comprising ##STR00002##
reacting a compound represented by formula (II) with a compound represented by formula (III) in the presence of a condensation agent to obtain a compound represented by formula (I).
Compound contained in manuka honey and use of same
The present description discloses a novel biologically active ingredient of manuka honey. Specially, the present description discloses a compound represented by the following formula. In this formula, each of R.sub.1, R.sub.2 and R.sub.3 independently represents a hydrogen atom or optionally substituted C.sub.1-4 alkyl group, m represents an integer from 1 to 3, each of R.sub.4-m, R.sub.5-m and R.sub.6-m independently represents a hydrogen atom or optionally substituted C.sub.1-4 alkyl group, and each of R.sub.7, R.sub.8, R.sub.9 and R.sub.10 independently represents a hydrogen atom or optionally substituted C.sub.1-4 alkyl group. ##STR00001##